ADH1A and hepatocellular carcinoma: Consistent downregulation of Alco_Met-GS in HCC tumors compared to adjacent normal tissues in patients from multiple datasets (Figure 5A), its ability to accurately distinguish between key features of HCC onset and progression (Figure 5B and Figure S6B), and its association with less aggressive disease state and good overall survival (Figures 5C–J) strongly suggest decreased expression of ADH1A and ALDH2 to be used as biomarker of disease onset and progression in HCC.